Press Release: Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Company to present an update of its ongoing

Dow JonesApr 24 22:05

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

First Data Demonstrating Application of PREDATOR Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (

GlobeNewswireApr 23 20:00

Buy Rating Affirmed for Werewolf Therapeutics on Promising PREDATOR Platform Prospects and Strong Pipeline Potential

TipRanksApr 19 22:06

All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy

Yahoo FinanceApr 16 00:00

Institutional Owners May Ignore Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Recent US$53m Market Cap Decline as Longer-term Profits Stay in the Green

Key Insights Institutions' substantial holdings in Werewolf Therapeutics implies that they have significant influence over the company's share price 50% of the business is held by the top 6 sharehol

Simply Wall StApr 13 22:39

Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)

TipRanksApr 11 01:50